GeneDx Holdings Corp. (NASDAQ: WGS) Investor Alert: Schubert Jonckheer Investigates Possible False Statements and Insider Trading

Schubert Jonckheer & Kolbe LLP advises GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to alleged false statements about its health intelligence platform called Centrellis.

On June 23, 2025, Judge Vernon D. Oliver of the U.S. District Court for the District of Connecticut ruled that a securities fraud lawsuit against GeneDx, its CEO, and former company executives could move forward. The lawsuit alleges that between January 2022 and August 2022, GeneDx (then named Sema4 Holdings Corp.) misled investors by falsely overstating the capabilities, potential, and commercial viability of Centrellis. These statements allegedly caused GeneDx’s stock to trade at artificially inflated prices. Judge Oliver found that the complaint sufficiently alleged that the defendants made false and misleading statements regarding Centrellis with an intent to defraud. During this period, various company insiders sold significant amounts of GeneDx stock. After the truth came out in August 2022 that GeneDx was significantly shifting its core R&D strategy and business model, its President was resigning, and the company was cutting 13% of its workforce, GeneDx’s stock price fell 33%.

We are investigating potential wrongdoing by GeneDx’s directors and officers in connection with these allegations.

If you own stock in GeneDx, you may have legal options. To learn more please fill out the form below.